|Study Description:||The goal of this clinical research study is to learn if the combination of 2 |
drugs dabrafenib and trametinib can help to control melanoma that has or has
not spread to the brain. The safety of this drug combination will also be
Dabrafenib is designed to block the mutated BRAF protein. This mutation is
only found in moles of the skin and in melanoma cells. By blocking the protein,
the drug may slow the growth of or kill cancer cells that have the protein.
Trametinib is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die.